Evaluation of the efficacy of gemfibrozil as an adjunct therapy in improving the symptoms of major depressive disorder

Phase 3

Recruiting

• Conditions: Major Depressive Disorder.; Major depressive disorder, single episode, severe without psychotic features; F32.2

• Registration Number: IRCT20090117001556N119
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 April 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Presence of Major Depressive Disorder based on DSM-5 criteria
Baseline Hamilton Depression Rating Scale (HAM-D) (17-item) score of at least 22
Age between 18 to 60 years

Exclusion Criteria

Presence of psychosis
Substanse use disorder except for nicotine and caffeine
IQ lower than 70
Any other mental disorder
Any significant neurologic or medical disease(advanced renal disease, CKD, hepatic disease, cardiovascular disease)
history of cholelithiasis
Receiving Warfarin
Recieving Insulin
Receiving statins
Receiving niacin

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of depression. Timepoint: Baseline and weeks 2,4 and 8. Method of measurement: by Hamiltion Depression Rating Scale 17-Item.